Jeffrey William Henderson

October 5, 2026

Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review. Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.

October 16, 2026

Qualcomm verdict adds to chip sector selloff. A legal verdict involving Qualcomm has contributed to a broader decline in the chip sector, with peers Arm and AMD falling 5%. This news adds pressure to the group, though Qualcomm is currently trading near its support level. The event highlights ongoing legal risks that can impact sentiment across the industry.

October 17, 2026

BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.

October 2, 2026

Kyntra Bio Names Andrew Singer to Board. Kyntra Bio has added Andrew E. Singer, MBA, to its board of directors. The move expands the company’s leadership team and could bring new expertise to its strategic planning. The appointment follows the company’s ongoing efforts to strengthen governance and support its growth initiatives. Investors may view the change as a sign of continued focus on development and operational improvement.